Trials / Completed
CompletedNCT04040348
Alzheimer's Disease Stem Cells Multiple Infusions
A Phase I, Prospective, Open-label Trial to Evaluate the Safety, Tolerability and Exploratory Outcomes of Multiple Allogeneic Human Mesenchymal Stem Cells (HMSC) Infusions in Patients With Mild to Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bernard (Barry) Baumel · Academic / Other
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to test the safety, possible side effects, and possible effectiveness of mesenchymal stem cell infusions when given to people with a diagnosis of mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Approximately 100 million cells allogeneic hMSC | Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion. |
Timeline
- Start date
- 2019-10-08
- Primary completion
- 2023-04-25
- Completion
- 2023-04-25
- First posted
- 2019-07-31
- Last updated
- 2025-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04040348. Inclusion in this directory is not an endorsement.